Exact Sciences Corp
NASDAQ:EXAS
Intrinsic Value
EXACT Sciences Corp. is a cancer screening and diagnostics company. [ Read More ]
The intrinsic value of one EXAS stock under the Base Case scenario is 62.33 USD. Compared to the current market price of 60.96 USD, Exact Sciences Corp is Undervalued by 2%.
Valuation Backtest
Exact Sciences Corp
Run backtest to discover the historical profit from buying and selling EXAS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Exact Sciences Corp
Current Assets | 1.2B |
Cash & Short-Term Investments | 777.6m |
Receivables | 203.6m |
Other Current Assets | 213.1m |
Non-Current Assets | 5.3B |
PP&E | 853.4m |
Intangibles | 4.3B |
Other Non-Current Assets | 166.1m |
Current Liabilities | 514.7m |
Accounts Payable | 78.8m |
Accrued Liabilities | 371.1m |
Other Current Liabilities | 64.8m |
Non-Current Liabilities | 2.8B |
Long-Term Debt | 2.3B |
Other Non-Current Liabilities | 489.6m |
Earnings Waterfall
Exact Sciences Corp
Revenue
|
2.5B
USD
|
Cost of Revenue
|
-654.2m
USD
|
Gross Profit
|
1.8B
USD
|
Operating Expenses
|
-2.1B
USD
|
Operating Income
|
-214.4m
USD
|
Other Expenses
|
10.2m
USD
|
Net Income
|
-204.1m
USD
|
Free Cash Flow Analysis
Exact Sciences Corp
What is Free Cash Flow?
EXAS Profitability Score
Profitability Due Diligence
Exact Sciences Corp's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
Exact Sciences Corp's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
EXAS Solvency Score
Solvency Due Diligence
Exact Sciences Corp's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Score
Exact Sciences Corp's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EXAS Price Targets Summary
Exact Sciences Corp
According to Wall Street analysts, the average 1-year price target for EXAS is 92.47 USD with a low forecast of 66.66 USD and a high forecast of 120.75 USD.
Ownership
EXAS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
EXAS Price
Exact Sciences Corp
Average Annual Return | -9.36% |
Standard Deviation of Annual Returns | 36.06% |
Max Drawdown | -80% |
Market Capitalization | 11.1B USD |
Shares Outstanding | 181 114 000 |
Percentage of Shares Shorted | 3.52% |
EXAS News
Last Important Events
Exact Sciences Corp
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Exact Sciences Corp
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 6,420 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection. The company offers laboratory testing services from its Cologuard colorectal cancer screening test, Oncotype DX cancer diagnostic tests and services, and COVID-19 test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its portfolio of Oncotype tests consist of Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect test, a liquid-based test for advanced stage prostate cancer; Oncotype MAPTM Pan-Cancer Tissue test; and GEM ExTra test. The company is developing a blood-based biomarker test to serve as an alternative to ultrasound and alpha-fetoprotein (AFP) for use in Hepatocellular Carcinoma (HCC) testing.
Contact
IPO
Employees
Officers
The intrinsic value of one EXAS stock under the Base Case scenario is 62.33 USD.
Compared to the current market price of 60.96 USD, Exact Sciences Corp is Undervalued by 2%.